Study: Gleevec may boost efficacy of stroke therapy

06/22/2008 | Reuters

An international team of scientists who induced stroke in mice found that those that received Novartis AG's leukemia drug Gleevec experienced 33% less blood vessel leakage linked to tissue plasminogen activator, a clot-dissolving drug. The findings suggest that Gleevec may help reduce tPA-related adverse events and increase the number of patients who could receive the stroke therapy. The researchers plan to begin human trials of the drug combination in the next few months.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC